340B Essentials: Understanding the 340B Program

Wednesday, December 17, 2025, 2:00 PM - 3:00 PM, Pharmacy Conference Room

1. Describe 340B program structure, including eligibility requirements
2. Review 340B program oversight and compliance
3. Recognize the benefits of 340B programs to institutions such as St. Jude

1. Describe 340B program structure, including eligibility requirements
2. Review 340B program oversight and compliance
3. Recognize the benefits of 340B programs to institutions such as St. Jude

Webex: Click Here

Reminders for claiming CE (may need to edit if non-stjude staff are attending):

• Text attendance code during presentation (15 mins before/2 hours after).

• Log in to your CloudCME profile and complete the test and evaluation (ideally within 1 week of presentation).

• DO NOT USE the ‘claim credit’ feature on CloudCME, as this is not configured for pharmacy use.

The St. Jude Children’s Research Hospital Department of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  

St. Jude Children’s Research Hospital designates this for a maximum of 1.00 CPE hours (0.1 CEU per 1 CPE hour).

Pharmacy continuing education credit will be available to all participants who attend, text attendance, and complete a program assessment and evaluation. Credits will be uploaded and viewable on-line at www.napb.net within approximately two weeks following the date of the presentation.  Participants should contact the CPE staff if credit does not appear within 4 weeks of a program.

 

ACPE - Accreditation Council for Pharmacy Education (1.00 hours)

Mitigation of Relevant Financial Relationships

St Jude Children's Research Hospital adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (ie, companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.